Drug resistance in leishmaniasis: its implication in systemic chemotherapy of cutaneous and mucocutaneous disease
about
In vitro activities of iboga alkaloid congeners coronaridine and 18-methoxycoronaridine against Leishmania amazonensisIn vitro susceptibility to pentavalent antimony in Leishmania infantum strains is not modified during in vitro or in vivo passages but is modified after host treatment with meglumine antimoniate.Physiological consequences of drug resistance in Leishmania and their relevance for chemotherapyDecentralized control of human visceral leishmaniasis in endemic urban areas of Brazil: a literature reviewPathways of As(III) detoxification in Saccharomyces cerevisiae.Efficacy of the herbicide trifluralin against four P-glycoprotein-expressing strains of LeishmaniaTesting of four Leishmania vaccine candidates in a mouse model of infection with Leishmania (Viannia) braziliensis, the main causative agent of cutaneous leishmaniasis in the New World.Is paromomycin an effective and safe treatment against cutaneous leishmaniasis? A meta-analysis of 14 randomized controlled trials.Protein network prediction and topological analysis in Leishmania major as a tool for drug target selection.Molecular Docking and in Vitro Antileishmanial Evaluation of Chromene-2-thione Analogues.Use of an attenuated leishmanial parasite as an immunoprophylactic and immunotherapeutic agent against murine visceral leishmaniasisIn vitro effects of Warburgia ugandensis, Psiadia punctulata and Chasmanthera dependens on Leishmania major promastigotesNovel low-cost thermotherapy for cutaneous leishmaniasis in PeruDecreased effect of glucantime in cutaneous leishmaniasis complicated with secondary bacterial infectionIn vitro sensitivity of paired Leishmania (Viannia) braziliensis samples isolated before meglumine antimoniate treatment and after treatment failure or reactivation of cutaneous leishmaniasisMicrotubule inhibitors: structure-activity analyses suggest rational models to identify potentially active compoundsIn vivo efficacy of oral and intralesional administration of 2-substituted quinolines in experimental treatment of new world cutaneous leishmaniasis caused by Leishmania amazonensisLeishmania and human immunodeficiency virus coinfection: the first 10 yearsHuman antiprotozoal therapy: past, present, and future.Antimony resistance in leishmania, focusing on experimental research.Efficacy of thermotherapy to treat cutaneous leishmaniasis: a meta-analysis of controlled clinical trials.Herbicides to curb human parasitic infections: in vitro and in vivo effects of trifluralin on the trypanosomatid protozoansLeishmaniases of the New World: current concepts and implications for future researchParasites and immunotherapy: with or against?Immunological determinants of clinical outcome in Peruvian patients with tegumentary leishmaniasis treated with pentavalent antimonials.An ATP-dependent As(III)-glutathione transport system in membrane vesicles of Leishmania tarentolae.Stage-specific activity of pentavalent antimony against Leishmania donovani axenic amastigotes.DNA transformation of Leishmania infantum axenic amastigotes and their use in drug screeningAntileishmanial activity of an indole alkaloid from Peschiera australis.Antimonial-mediated DNA fragmentation in Leishmania infantum amastigotes.Flow cytometric detection of Leishmania parasites in human monocyte-derived macrophages: application to antileishmanial-drug testing.Duplex quantitative Reverse-Transcriptase PCR for simultaneous assessment of drug activity against Leishmania intracellular amastigotes and their host cellsGene amplification in Leishmania tarentolae selected for resistance to sodium stibogluconate.Sensitivity of Leishmania viannia panamensis to pentavalent antimony is correlated with the formation of cleavable DNA-protein complexesAxenically grown amastigotes of Leishmania infantum used as an in vitro model to investigate the pentavalent antimony mode of action.An axenic amastigote system for drug screeningAxenically cultured amastigote forms as an in vitro model for investigation of antileishmanial agents.In vitro life cycle of pentamidine-resistant amastigotes: stability of the chemoresistant phenotypes is dependent on the level of resistance inducedTrypanothione reductase: a viable chemotherapeutic target for antitrypanosomal and antileishmanial drug design.Inhibition of Leishmania major PTR1 Gene Expression by Antisense in Escherichia coli.
P2860
Q24536041-0F12F1CB-342E-4A8D-BC82-A28E1971A883Q24792826-87475F9C-5673-4E90-A972-FCB358E20E78Q24796588-74D3A959-4D11-4CC8-93F4-222F65AB322DQ26739026-FE9887A6-8657-4391-A2C9-359AE938009BQ27931719-949839F2-1AA6-4533-8ED1-2702074C1FE0Q28367464-C1FD0E01-0463-4FD3-A0D0-8DF9C86E8AE4Q30444062-51C2E55C-FBBC-4FE7-A130-75C73BF1B491Q33409844-21DC2C19-F8EA-40D9-AC98-17DCFC8976CDQ33704536-4915B556-24B4-427B-B5F6-F9DBEC4A9F3BQ33752764-0EF3CF47-C0C0-4B24-B7BC-2B307A0F03C6Q33998229-77E4289B-2D25-476F-A9C2-F1C7DDB584A8Q34514152-66A558E1-35D4-4DFB-9E14-EDDFFCD73CD4Q34713385-37453D87-6655-43D3-8FB3-EE8F2CC5BCF8Q34941761-86CD7197-7D93-4D15-B706-94FDC9E0CC2CQ35087276-9F3C792D-ACF1-4554-A3D8-A48759086EECQ35123745-3F70F95C-F544-47C8-823C-8A4DCFAE35E2Q35128720-D3666275-FDFB-4CD8-8770-40AA6ABD8246Q35374078-DEE96DB0-D436-4A3E-AF7A-793314E4E107Q35535171-AE5200CD-2FD9-4DDA-B140-76A57BB5DB6BQ35607561-F830BD29-9C32-4ED6-B225-B7D48F5DB8DFQ35640976-0331B87C-B3A1-4D6D-8CCA-9CAA1352E80CQ36368817-BB966B57-EEE6-4D07-8B6D-85F6DEF47E8CQ36640255-93ACF1CF-D6A7-4C6C-8CB6-546E41433070Q37053248-71268A29-9B15-4054-BE89-8BFAA4E1C258Q37191345-4AB4DD11-FE43-435A-8952-C2A5622BC657Q37713114-4BDF9428-87B1-424C-B13E-AA10722D2A65Q39469739-B538BB86-9075-4527-8944-CE6B3F94EA49Q39476913-FDFCD319-E89E-47A6-95BA-1D02CDBF1806Q39477065-9350A18F-159D-4648-B24C-0D8C412B15E6Q39477783-8CA8062A-7B65-473C-8D5D-D444C04DB9F4Q39537187-95892875-DAB5-48D6-AF47-BB8ECEE21E6EQ39548200-1457BDA0-0099-4C50-9720-7D4302DEEF0EQ39557983-4946485A-5B75-458B-BA90-2D927DA08F73Q39558272-1671AD87-B0C7-4F67-8784-01182365395CQ39559595-0CA9ADF0-BCE9-437F-8297-7B1903AF89C3Q39783960-5CF6A7FA-3318-40D7-B74B-053B5832D2E8Q39784088-2DF8A3EB-D536-4585-9378-A0487BE67E56Q39784844-3395B568-C1F4-4CF2-AB89-1CF98E8A5523Q40255801-93BC99EA-6544-4E0B-883F-4F7BF5B0ED8BQ42429879-80D52B86-6837-4C71-A97A-3C45851C9109
P2860
Drug resistance in leishmaniasis: its implication in systemic chemotherapy of cutaneous and mucocutaneous disease
description
1992 nî lūn-bûn
@nan
1992 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
1992 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
name
Drug resistance in leishmanias ...... eous and mucocutaneous disease
@ast
Drug resistance in leishmanias ...... eous and mucocutaneous disease
@en
Drug resistance in leishmanias ...... eous and mucocutaneous disease
@nl
type
label
Drug resistance in leishmanias ...... eous and mucocutaneous disease
@ast
Drug resistance in leishmanias ...... eous and mucocutaneous disease
@en
Drug resistance in leishmanias ...... eous and mucocutaneous disease
@nl
prefLabel
Drug resistance in leishmanias ...... eous and mucocutaneous disease
@ast
Drug resistance in leishmanias ...... eous and mucocutaneous disease
@en
Drug resistance in leishmanias ...... eous and mucocutaneous disease
@nl
P2093
P3181
P1476
Drug resistance in leishmanias ...... eous and mucocutaneous disease
@en
P2093
P304
P3181
P407
P577
1992-07-01T00:00:00Z